StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Stock analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a report on Thursday, November 14th.

Trevena Stock Down 9.2 %

Shares of NASDAQ TRVN opened at $1.48 on Friday. The stock has a fifty day moving average price of $1.80 and a 200 day moving average price of $4.40. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The firm had revenue of $0.28 million for the quarter. As a group, sell-side analysts expect that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.